Linadus M XR
Generic Name
Linagliptin + Metformin Hydrochloride (Extended Release)
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| linadus m xr 5 mg tablet | ৳ 24.00 | ৳ 144.00 |
Description
Overview of the medicine
Linadus M XR is an oral anti-diabetic medication used for the management of type 2 diabetes mellitus. It combines Linagliptin, a DPP-4 inhibitor, and Metformin Hydrochloride, a biguanide, to improve glycemic control through complementary mechanisms of action. The XR formulation provides extended release of Metformin.
Uses & Indications
Dosage
Adults
One tablet (e.g., Linagliptin 2.5 mg/Metformin HCl 1000 mg XR) once daily with food, preferably in the evening. Dosage should be individualized based on efficacy and tolerability, not exceeding 5 mg Linagliptin and 2000 mg Metformin HCl XR daily.
Elderly
Close monitoring of renal function is advised. Dosage adjustments may be necessary due to potential age-related decline in renal function.
Renal_impairment
Not recommended in patients with eGFR <30 mL/min/1.73 m². Dose adjustment needed for eGFR 30-60 mL/min/1.73 m² (e.g., max 1000 mg Metformin XR daily).
How to Take
Take orally once daily with a meal, preferably in the evening, to reduce gastrointestinal side effects. Swallow the tablet whole; do not crush, cut, or chew.
Mechanism of Action
Linagliptin selectively inhibits the enzyme Dipeptidyl Peptidase-4 (DPP-4), leading to increased levels of active incretin hormones (GLP-1 and GIP). These hormones enhance glucose-dependent insulin secretion and suppress glucagon release. Metformin reduces hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Pharmacokinetics
Onset
Glycemic control improvement within weeks.
Excretion
Linagliptin is primarily eliminated unchanged via the enterohepatic system. Metformin is eliminated unchanged renally.
Half life
Linagliptin: Approximately 12-16 hours. Metformin: Approximately 6.2 hours (plasma), extended in XR formulation.
Absorption
Linagliptin is rapidly absorbed with peak plasma concentrations reached in 1.5 hours. Metformin XR absorption is extended, with peak concentrations reached in 4-8 hours.
Metabolism
Linagliptin is minimally metabolized. Metformin is not metabolized in humans.
Side Effects
Contraindications
- •Hypersensitivity to Linagliptin or Metformin
- •Severe renal impairment (eGFR <30 mL/min/1.73 m²)
- •Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma
- •Acute conditions with potential for renal impairment (e.g., dehydration, severe infection, shock)
- •Hepatic impairment
- •Acute myocardial infarction, septicemia
Drug Interactions
Alcohol
Increases risk of lactic acidosis with Metformin.
Rifampicin
May decrease efficacy of Linagliptin.
Carbonic Anhydrase Inhibitors (e.g., Topiramate, Acetazolamide)
May increase risk of lactic acidosis with Metformin.
Cationic drugs (e.g., Amiloride, Digoxin, Morphin, Procainamide, Quinidine, Quinine, Ranitidine, Triamterene, Trimethoprim, Vancomycin)
May increase Metformin concentrations.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Overdose of Metformin can lead to lactic acidosis, which is a medical emergency. Symptomatic and supportive treatment is necessary. Hemodialysis is effective for removing Metformin. Linagliptin overdose is unlikely to cause adverse effects beyond minimal gastrointestinal symptoms.
Pregnancy & Lactation
Pregnancy Category B for Linagliptin, Category B for Metformin. Limited data on human pregnancy. Use only if clearly needed. Not recommended during breastfeeding as Metformin is excreted in breast milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24-36 months
Availability
Available in pharmacies nationwide
Approval Status
Approved by regulatory authorities (e.g., FDA, DGDA)
Patent Status
Patent protected (for combination in some regions), generic versions may be available in others.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in